• Home
  • About
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • PAS-004
    • NF1
    • Presentations & Publications
  • Patients
    • Clinical Trials
    • Expanded Access
  • Investors
  • Contact

Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments

by divibasicbldev | Jan 26, 2022 | Press Releases

In-person clinic will provide ketamine therapy and other novel mental health treatments, including repeated transcranial magnetic stimulation (“rTMS”)MIAMI BEACH, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA)...

Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom

by divibasicbldev | Dec 21, 2021 | Press Releases

— Expanding Pasithea Clinics footprint in London –MIAMI BEACH, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the...

Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada

by divibasicbldev | Dec 1, 2021 | Press Releases

— Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada — — Treatments conducted by board-certified medical professionals — — Expansion to additional U.S. cities in coming months — MIAMI BEACH, Fla.,...

Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

by divibasicbldev | Nov 29, 2021 | Press Releases

MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for...

Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

by divibasicbldev | Nov 24, 2021 | Press Releases

MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for...

Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.

by divibasicbldev | Nov 23, 2021 | Press Releases

Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disordersMIAMI BEACH, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA)...
« Older Entries
Next Entries »

Recent Posts

  • Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
  • Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
  • Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
  • Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
  • Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Recent Comments

No comments to show.
Email Alerts

© Pasithea Therapeutics Corp. All Rights Reserved.